Long-term treatment with picotamide 300 mg t.i.d. maintained significant inhibition of platelet aggregation (-30% vs placebo at 24 months) in 86% of type 2 diabetic patients.
RCT (n=50)
Double-blind
Randomized
Does picotamide 300 mg t.i.d. maintain antiaggregatory effects compared to placebo in type 2 diabetic patients over 2 years?
Long-term treatment with picotamide maintains significant antiplatelet effects over 2 years in patients with type 2 diabetes, with a potential reduction in thrombotic events.
Effect estimate: -30% vs placebo
The ex vivo antiaggregatory activity of picotamide, a dual antithromboxane agent, was assessed to find whether it was maintained in long-term treatment. In a double-blind, placebo-controlled 2-year study, 50 type 2 diabetic patients (35 men and 15 women; mean age 66 +/- 5 years) were enrolled and randomly given picotamide, 300 mg t.i.d. or the corresponding placebo. Platelet aggregation studies were performed at baseline and after 1, 3, 6, 12, 18 and 24 months. Compliance to the treatment was assessed by pill count at each visit. Forty-nine patients concluded the study. Starting from month 1, compared with placebo, picotamide-treated patients showed a significant inhibition of agonist-induced (ADP, arachidonic acid and collagen) platelet aggregation (-41%). The antiaggregatory effect was maintained throughout the study. At month 24, in the picotamide group, platelet aggregation was significantly lower compared with placebo (-30%). After 24 months of treatment, 20 out of 23 (86%) picotamide-treated patients showed a significant inhibition of platelet aggregation, whereas the remaining three patients had a normal platelet response. During the study, 12 patients suffered from thrombotic events of death: nine in the placebo group and three in the picotamide group, respectively. It was concluded that picotamide maintains its antiaggregatory effect, in long-term treatment, in more than 85% of patients.
Cocozza et al. (Sat,) conducted a rct in Type 2 diabetes (n=50). Picotamide vs. Placebo was evaluated on platelet aggregation at 24 months (-30% vs placebo). Long-term treatment with picotamide 300 mg t.i.d. maintained significant inhibition of platelet aggregation (-30% vs placebo at 24 months) in 86% of type 2 diabetic patients.